Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00255424Phase 3Completed
Phase 3, randomised, open-label trial of ferumoxytol in anemia (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Mean change in hemoglobin from baseline at Day 35. Started May 2004; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00255424.